Urgent Warning Issued After Detection of New Mpox Strain in the UK
Urgent Warning Issued After Detection of New Mpox Strain in the UK
The UK Health Security Agency (UKHSA) has confirmed the detection of four cases of the Clade Ib strain of mpox, marking the first cluster of this variant outside Africa. All cases were found within the same household in London. While the risk to the general UK population remains low, health officials are closely monitoring the situation due to the strain's higher transmissibility and potential severity compared to previously seen variants
Clade Ib is a variant of the mpox virus, which has primarily circulated in the Democratic Republic of Congo and neighboring African countries. It is more transmissible than the Clade II strain that has been sporadically detected in the UK since 2022. Symptoms include fever, muscle aches, and a distinctive rash that can evolve into painful lesions. Transmission occurs through close physical contact, contaminated surfaces, or prolonged face-to-face interactions.
The first case was linked to recent travel in Africa, where the strain has caused significant outbreaks. Symptoms appeared days after the individual returned to the UK, and the infection spread to three household contacts. The affected individuals are under specialist care, and close contacts have been identified, tested, and offered vaccination to prevent further spread. UKHSA has reassured the public that the containment measures in place are robust.
The World Health Organization (WHO) declared the spread of Clade Ib a public health emergency earlier this year due to outbreaks in multiple countries. Over 40,000 cases and nearly 1,000 deaths linked to mpox were reported across Africa by September 2024. The emergence of cases in Europe signals the need for heightened surveillance and rapid response measures.
Health authorities emphasize that the overall risk to the public remains low. However, individuals are advised to monitor for symptoms, particularly if they have traveled to affected regions or had close contact with confirmed cases. Vaccines and public health protocols are being employed to limit transmission.
The UKHSA continues to work with the NHS and international partners to address this new threat while ensuring the public remains informed and protected.
